Navigation Links
Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics' Human Pilot Study
Date:12/13/2012

RENSSELAER, N.Y., Dec. 13, 2012 /PRNewswire-iReach/ -- Ultradian Diagnostics LLC, an early-stage medical device company based in Rensselaer, New York, today announced the publication of clinical study results for Biologue, the Company's minimally invasive continuous glucose monitoring (CGM) system, in the November 2012 issue of the Journal of Diabetes Science and Technology. In the peer-reviewed article entitled "Pilot Study of a Prototype Minimally Invasive Intradermal Continuous Glucose Monitor," the authors report the Biologue provided clinically accurate results 98.9% of the time and was well tolerated by study participants, with no pain and no adverse events observed. The study was funded in part by a National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Business Catalyst grant and conducted by investigators from the State University of New York Upstate Medical University and Ultradian Diagnostics.

The study demonstrated clinical proof of concept for Ultradian's Biologue CGM using a proprietary single point calibration method and unique biofouling correction algorithm. "We believe this publication validates our novel approach to improved accuracy and methods to mitigate the in vivo effects of sensor biofouling," said Dr. John Willis, CEO of Ultradian Diagnostics. "The accuracy and tolerance data from this pilot study is very positive and represents a significant milestone on our path to develop a user calibration-free CGM capable of interfacing with an insulin pump to form the long-sought, closed-loop Artificial Pancreas."

The full article is available on the Journal of Diabetes Science and Technology website: (www.journalofdst.org).

About Ultradian Diagnostics

Ultradian is a medical device company developing continuous, wireless, wearable biosensors for monitoring chronic illnesses. The Company was founded to improve the accuracy of minimally invasive biosensors so they may be used at the bedside in hospitals and by people for self-monitoring of chronic illnesses. Ultradian's initial product, called Biologue, is a minimally invasive biosensor system that continuously measures glucose within the skin. Biologue is a platform technology where components of the core system can be leveraged into other product opportunities. Ultradian is actively seeking strategic partners to accelerate commercial introduction of their continuous monitoring technologies. For more information about Ultradian Diagnostics, please visit www.ultradian.com.

Media Contact: John P. Willis, CEO Ultradian Diagnostics LLC, 518-312-7852, jwillis@ultradian.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE Ultradian Diagnostics LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Bio Implements Major Balance Sheet Clean-Up
2. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
3. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
4. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
5. Research could lead to new drugs for major diseases
6. APCER Pharma Sponsors Major Industry Conference
7. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
8. Promotion of Young Researchers Supported by Major Donation
9. Kitty Castellini Wins Roche Diabetes Cares Diabetes Heroes Torchbearer Challenge
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... in patients with catheters associated with peritoneal dialysis, announced today that it has ... dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal ...
(Date:2/18/2017)... -- Kurzlehrgang mit Fokus auf Assay ... legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... ... Yoav Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang ... Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der ...
(Date:2/17/2017)... FREMONT, Calif. , Feb. 17, 2017 /PRNewswire/ ... pleased to announce development of a novel system ... in collaboration with the University of Rochester (NY, ... ). The new system is able to ... cancer biomarker, HER2 (Human epidermal growth factor receptor-2) ...
(Date:2/16/2017)... Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 Venture ... by a MichBio member organization. They provide an opportunity to interact with peers, make ...
Breaking Biology Technology:
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
Breaking Biology News(10 mins):